1. Rosen Law Firm announces a class action against Merck over misleading revenue statements. 2. Merck is accused of concealing low demand for Gardasil in China. 3. Investors may claim compensation with no upfront fees if eligible. 4. Class action lead plaintiff deadline is April 14, 2025. 5. Investors represented by Rosen Law Firm have seen substantial recoveries in past cases.
The allegations of misleading revenue forecasts can undermine investor confidence in MRK.
The class action could lead to financial repercussions and market uncertainty for MRK.
Immediate market reactions are likely as the lawsuit progresses, especially pre-deadline.
NEW YORK, April 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline.
If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
To join the Merck class action, go to https://rosenlegal.com/submit-form/?case_id=34975 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' statements included, among other things, confidence in Merck's purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil's growth in China. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Gardasil's demand in China; notably, that Merck lacked visibility into demand for Gardasil in China among eligible and otherwise targeted populations, resulting in the inflated inventory of its distributor, Zhifei. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Merck class action, go to https://rosenlegal.com/submit-form/?case_id=34975 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: 866-767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.